Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats
Authors:
- 1 June 2004
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 56 (6) , 809-812
Abstract
The purpose of this study was to modulate the pharmacokinetics of irinotecan metabolites, SN-38 and SN-38-glucuronide, by possibly reducing biliary excretion, which in turn could lower irinotecan toxicity. SN-38-glucuronide is associated with severe diarrhoea that occurs after irinotecan therapy as a result of enteric injury caused by SN-38. Sulphobromophthalein is used clinically as a drug for testing liver function and is considered to be a safe drug. We investigated the effect of sulphobromophthalein on the disposition of irinotecan metabolites after CPT-11 (7-ethyl-10-[10-4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin) administration. Wistar rats were administered CPT-11 (500 μg/body) in saline as a bolus injection into the femoral vein through a catheter. The volume of drug solution injected into each animal was 1 mL. Rats were either administered CPT-11 alone or simultaneously with sulphobromophthalein (20mg/body). After administration, blood and bile samples were taken at appropriate intervals and analysed by HPLC. Co-administration of sulphobromophthalein partially inhibited the biliary excretion of SN-38-glucuronide with a concomitant increase in its area under the plasma concentration-time curve (AUC) but did not significantly alter the biliary excretion and AUC of the active metabolite SN-38. These results suggested that cotreatment of CPT-11 with sulphobromophthalein might decrease intraluminal SN-38 concentrations without altering the pharmacokinetics of SN-38.Keywords
This publication has 6 references indexed in Scilit:
- Mechanism of Active Secretion of Phenolsulfonphthalein in the Liver via Mrp2 (abcc2), an Organic Anion TransporterDrug Metabolism and Pharmacokinetics, 2003
- Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver CarboxylesteraseBiochemical Pharmacology, 1996
- Protective Effects of Kampo Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrochloride (CPT‐11), in RatsJapanese Journal of Cancer Research, 1995
- Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control DiarrheaJNCI: Journal of the National Cancer Institute, 1994
- Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretionXenobiotica, 1991
- Urinary Elimination of Bromsulfalein in ManScandinavian Journal of Clinical and Laboratory Investigation, 1961